## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.66 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (57% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($94.51)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Overweight Rating**
- Source: marketscreener.com | 20251215T150842 | Somewhat-Bullish | Relevance: 100%
- Barclays has increased its price target for Revvity to $115 from $105, while reiterating an Overweight rating on the stock. This adjustment comes amidst other analyst activities, including Wells Fargo also raising its price target and BofA Securities downgrading the stock. Revvity specializes in medical diagnosis and analytical equipment, with significant operations in the US and China.

**2. Revvity stock rating downgraded to Neutral by BofA Securities**
- Source: Investing.com | 20251215T130845 | Bearish | Relevance: 100%
- BofA Securities downgraded Revvity Inc (NYSE:RVTY) from Buy to Neutral, citing limited upside potential due to challenges in its China diagnostics business and a modest 2026 outlook. Despite the downgrade, the new price target of $110.00 still suggests a 9.5% upside from current levels. The firm recommends investors explore other opportunities in the tools sector for now, despite Revvity exceeding Q3 EPS expectations and acquiring ACD/Labs.

**3. Revvity (NYSE:RVTY) Lowered to "Neutral" Rating by Bank of America**
- Source: MarketBeat | 20251215T154144 | Somewhat-Bearish | Relevance: 100%
- Bank of America has downgraded Revvity (NYSE:RVTY) from a "buy" to a "neutral" rating, setting a $110 price target, which implies an 11.7% upside. Despite this, the consensus analyst rating remains "Hold" with an average price target of $115.25. The company recently approved a $1.0 billion share buyback program and issued FY2025 EPS guidance, trading near $98.45 with a P/E of approximately 49.3.

**4. Revvity stock rating downgraded to Neutral by BofA Securities**
- Source: Investing.com India | 20251215T130254 | Somewhat-Bearish | Relevance: 100%
- BofA Securities downgraded Revvity Inc. (NYSE:RVTY) from Buy to Neutral, citing limited upside potential despite raising its price target to $110.00. The firm highlighted Revvity's high P/E ratio, 2026 outlook of 2-3% topline growth and 28% margins, and challenges in its China diagnostics business as reasons for the downgrade. Despite the downgrade, the new price target implies a 9.5% upside from current trading levels of $100.49.

**5. EdgePoint Investment Group Inc. Boosts Stock Position in Revvity Inc. $RVTY**
- Source: MarketBeat | 20251213T110823 | Bullish | Relevance: 100%
- EdgePoint Investment Group Inc. significantly increased its stake in Revvity Inc. ($RVTY) by 26.7% in Q2, acquiring over 1.4 million shares and making Revvity its ninth-largest holding. This move comes as Revvity announced a $1 billion share buyback plan, reported strong Q2 earnings beating estimates, and provided positive FY2025 guidance. Other institutional investors have also adjusted their holdings in the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.66 indicates undervaluation relative to growth. Forward P/E 18.9x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.7B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.66 |
| Forward P/E | 18.9 |
| Current P/E | 20.4 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. Volume at 57% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.41% (CS: 41) | Neutral |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.054x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $100.49
- **Stop Loss:** $94.51 (6.0% risk)
- **Target:** $112.45 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $16,781.83
- **Portfolio %:** 16.78%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*